证券之星消息，截至2025年10月16日收盘，美好医疗(301363)报收于23.13元，下跌0.04%，换手率 1.55%，成交量5.78万手，成交额1.34亿元。 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-16 | 23.13 -0.04% | 1304.85万 | 9.72% | -231.42万 | -1.72% | -1073.43万 | -8.00% | | 2025-10-15 | 23.14 2.71% | · 195.35万 | 1.57% | -630.18万 | -5.06% | 434.83万 | 3.49% | | 2025-10-14 | 22.53 -3.22% | -143.55万 | -0.84% | -555.08万 | -3.26% | 698.63万 | 4.10% | | 2025-10-13 | 23.28 -2.10% | -1537.41万 | -12.01% | -2 ...

证券之星消息，截至2025年9月12日收盘，美好医疗(301363)报收于26.06元，下跌1.88%，换手率 6.82%，成交量10.65万手，成交额2.78亿元。 9月12日的资金流向数据方面，主力资金净流入3117.42万元，占总成交额7.33%，游资资金净流出 2041.38万元，占总成交额4.8%，散户资金净流出1076.04万元，占总成交额2.53%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-12 | 26.36 -0.75% | 3117.42万 | 7.33% | -2041.38万 | -4.80% | -1076.04万 | -2.53% | | 2025-09-11 | 26.56 0.23% | -2282.08万 | -4.88% | 2144.83万 | 4.59% | 137.24万 | 0.29% | | 2025-09-10 | 26.50 6.98% ...

Group 1 - The stock of Meihao Medical (301363) closed at 24.6 yuan on September 3, 2025, down 1.4% with a turnover rate of 9.95% and a trading volume of 155,500 hands, resulting in a transaction amount of 387 million yuan [1] - On September 3, 2025, the net inflow of main funds was 23.1 million yuan, accounting for 5.97% of the total transaction amount, while retail investors had a net outflow of 27.2 million yuan, accounting for 7.03% [1] - Over the past five days, the stock has experienced fluctuations in both main and retail fund flows, with notable changes in net inflows and outflows [1] Group 2 - Meihao Medical's total market value is 13.994 billion yuan, which is higher than the industry average of 11.994 billion yuan, ranking 24th out of 123 in the medical device industry [2] - The company's net profit for the first half of 2025 was 114 million yuan, a decrease of 32.44% year-on-year, while its main revenue was 733 million yuan, an increase of 3.73% year-on-year [2] - The company reported a gross profit margin of 37.52%, which is significantly lower than the industry average of 51.85%, ranking 93rd out of 123 [2] Group 3 - In the last 90 days, 16 institutions have rated the stock, with 14 buy ratings and 2 hold ratings, and the average target price set by institutions is 26.48 yuan [3]

Core Viewpoint - As of September 1, 2025, Meihao Medical (301363) closed at 25.21 yuan, marking a 4.65% increase, with significant trading activity and mixed capital flows [1][2]. Group 1: Stock Performance - On September 1, 2025, the stock price increased by 4.65% with a trading volume of 271,900 hands and a total transaction amount of 671 million yuan [1]. - The stock experienced a net inflow of 75.38 million yuan from main funds, accounting for 11.23% of the total transaction amount, while retail investors saw a net outflow of 110 million yuan, representing 16.39% of the total [1][2]. Group 2: Financing and Margin Trading - On September 1, 2025, the financing buy amounted to 81.20 million yuan, with a net financing buy of 715,000 yuan, while the margin trading balance stood at 1.59 billion yuan [2][3]. - The stock's margin trading data indicated a total of 3.72 million shares in margin trading, with a margin balance of 937,300 yuan [3]. Group 3: Financial Metrics and Industry Comparison - Meihao Medical reported a total market value of 14.34 billion yuan, with a net profit of 114 million yuan, reflecting a year-on-year decline of 32.44% [5]. - The company's gross profit margin was 37.52%, significantly lower than the industry average of 51.85%, while its net profit margin was 15.6%, higher than the industry average of 10.39% [5]. - The company’s return on equity (ROE) was 3.23%, outperforming the industry average of 1.8% [5]. Group 4: Institutional Ratings - In the last 90 days, 16 institutions rated the stock, with 14 buy ratings and 2 hold ratings, and the average target price set at 26.48 yuan [6].

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 25.16 yuan on August 28, 2025, down 1.64% from the previous day, indicating a volatile trading environment and mixed investor sentiment [1]. Financial Performance - For the first half of 2025, Meihao Medical reported a main revenue of 733 million yuan, a year-on-year increase of 3.73%, while the net profit attributable to shareholders was 114 million yuan, a decrease of 32.44% [3]. - In Q2 2025, the company achieved a single-quarter main revenue of 437 million yuan, up 2.86% year-on-year, but the net profit attributable to shareholders fell by 43.83% to 62.43 million yuan [3]. - The company's gross profit margin stands at 37.52%, which is significantly lower than the industry average of 51.86% [3]. Market Position and Valuation - Meihao Medical's total market capitalization is 14.31 billion yuan, which is above the industry average of 12.06 billion yuan, ranking 23rd out of 123 companies in the medical device sector [3]. - The company's price-to-earnings (P/E) ratio is 62.61, which is lower than the industry average of 70.48, ranking 63rd in the industry [3]. - The price-to-book (P/B) ratio is 3.98, slightly above the industry average of 3.89, ranking 86th [3]. Investor Sentiment and Fund Flow - On August 28, 2025, the net outflow of main funds was 31.03 million yuan, accounting for 5.15% of the total transaction volume, while retail investors saw a net inflow of 29.83 million yuan, representing 4.95% of the total [1][2]. - Over the past 90 days, 15 institutions have rated the stock, with 13 buy ratings and 2 hold ratings, indicating a generally positive outlook among analysts [4].